|
Description
Oasmia Pharmaceutical, Sweden and Orion Corporation, Finland, have entered a license and distribution agreement for marketing and sales of the human cancer drug Paclical(R) (micellar paclitaxel) in the Nordic region, encompassing Sweden, Denmark, Norway, Finland and Iceland. The product is currently entering Phase III development by Oasmia, with ovarian cancer as the target indication.
Orion receives the exclusive rights in the Nordic region to distribute and sell the product. Orion will also have first right of refusal for one more cancer drug candidate in the Oasmia product portfolio in this region. According to the agreement, Oasmia will receive payments... |
More articles from Worldwide Biotech
FOVEA/GENZYME SIGN OPHTHALMOLOGY RESEARCH PACT., January 01, 2008
HEALTH CANADA ACCEPTS SANTHERA'S NDS FOR SNT-MC17., January 01, 2008
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
